Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Dolatrai Vyas, Ph.D. and Raymond Cohen to its board of directors at the Annual Meeting of Stockholders held on June 28, 2013.
“I am pleased and honored to welcome two industry leaders to the Board of Directors,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “Dr. Vyas’ proven expertise in drug discovery and development and Mr. Cohen’s proven leadership in the healthcare industry will be instrumental as we continue to grow.”
Dr. Vyas spent more than 30 years in oncology drug discovery and research at Bristol-Myers Squibb Company (NYSE: BMY), a leading pharmaceutical company, most recently as a Group Director and Distinguished Research Fellow. During his tenure at BMY in oncology drug discovery, he participated in the discovery and development of 12 small molecules and one antibody drug conjugate as clinical development candidates with one US Food and Drug Administration approved NDA.
Mr. Cohen brings to the Board of Directors over 28 years of experience as an executive in the healthcare industry, including serving as Executive Chairman or Chief Executive Officer at several prominent companies. Until November 2012, Mr. Cohen served as Chief Executive Officer at privately-held Laguna Hills, CA-based Vessix Vascular Inc., a developer of a novel percutaneous RF balloon catheter renal denervation system used to treat uncontrolled hypertension. Vessix was acquired by Boston Scientific Corporation (NYSE: BSX) in November 2012 in a structured transaction valued at up to $425 million. Mr. Cohen is currently the Executive Chairman of JenaValve Technology, Inc., a venture backed company in the transcatheter aortic valve business, and among other board appointments chairs the Audit committee on the board of BioLife Solutions Inc. (OTC: BLFS), a manufacturer and marketer of preservation media for human cells and tissue.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV